Advertisement
Advertisement

ZURA

ZURA logo

Zura Bio Limited Class A Ordinary Shares

4.80
USD
Sponsored
+0.05
+1.05%
May 13, 16:00 UTC -4
Closed
exchange

Pre-Market

5.00

+0.20
+4.17%

ZURA Earnings Reports

Positive Surprise Ratio

ZURA beat 5 of 12 last estimates.

42%

Next Report

Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.19
Implied change from Q1 26 (Revenue/ EPS)
--
/
-13.64%
Implied change from Q2 25 (Revenue/ EPS)
--
/
+11.76%

Zura Bio Limited Class A Ordinary Shares earnings per share and revenue

On May 07, 2026, ZURA reported earnings of -0.22 USD per share (EPS) for Q1 26, missing the estimate of -0.17 USD, resulting in a -23.94% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.16% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.19 USD, with revenue projected to reach -- USD, implying an decrease of -13.64% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
logo
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
logo
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
logo
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
logo
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
logo
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-
Actual
-$0.05
Surprise
-
logo
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
logo
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
logo
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
For Q1 2026, Zura Bio Limited Class A Ordinary Shares reported EPS of -$0.22, missing estimates by -23.94%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.16%, changed from $4.89 before the earnings release to $4.54 the day after.
The next earning report is scheduled for Aug 12, 2026.
Based on 8 analysts, Zura Bio Limited Class A Ordinary Shares is expected to report EPS of -$0.19 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement